1. Quick Facts
Category: Myostatin Inhibitor / Muscle Growth Regulator
Risk Level: High/Experimental
Research Status: Early-Stage Experimental
Administration: Subcutaneous Injection
Typical Frequency: Once Weekly
Estimated Half-Life: Approximately 10–15 Days
Primary Research Interest: Muscle Growth / Muscle Preservation
This material is provided strictly for educational and informational purposes related to experimental compounds and peptide research. ACE-031 is not approved for general human use and carries potentially significant health risks. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
ACE-031 is an experimental biologic compound designed to inhibit myostatin signaling, a regulatory pathway involved in limiting skeletal muscle growth.
The compound was originally investigated for potential applications involving muscle wasting disorders and conditions associated with severe muscle loss.
What People Commonly Claim
- Extreme muscle growth beyond natural limits
- Rapid increases in strength and lean mass
- Powerful “myostatin blocker” effects
- Potential use as a muscle-building alternative to anabolic steroids
- Enhanced recovery and athletic performance
What the Literature Actually Shows
- ACE-031 was developed as an experimental myostatin-pathway inhibitor intended to increase lean body mass.
- Early human studies demonstrated measurable increases in lean body mass and muscle volume.
- Development was ultimately discontinued because of safety concerns, including vascular side effects such as nosebleeds and small blood vessel abnormalities.
- Long-term safety and efficacy remain incompletely characterized.
- No approved medical use currently exists, and human data remain limited compared with established therapies.
3. Reconstitution Guide
- Vial Size: 1 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 1.0 mL
- Final Concentration: 1.0 mg/mL
At this concentration:
• 1 mg = 1.0 mL (100 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
ACE-031 has most commonly been discussed in research settings as a subcutaneous injectable compound.
- Primary Route: SubQ Injection
- Alternative Routes Discussed: None commonly referenced
- Injection Timing Notes: Long half-life may allow infrequent administration schedules.
5. Common Research Protocols
- Product Strength: 1.0 mg/mL
- Typical Delivered Amount: 1 mg once weekly
- Frequency: Once per week
- Cycle Length: 3 weeks on / 3 weeks off
- Special Notes: Clinical research used single ascending doses rather than bodybuilding-style protocols. In healthy volunteer studies, effects on lean mass markers were observed after single administrations, and the drug was ultimately discontinued partly because of safety concerns, including vascular side effects such as nosebleeds and small blood vessel changes.
6. Mechanism of Action
ACE-031 functions primarily as a modified activin receptor construct that binds signaling proteins involved in negative regulation of muscle growth, including myostatin and activin-family molecules.
By interfering with these pathways, ACE-031 was observed in early research to increase lean body mass and potentially enhance muscular hypertrophy.
7. Potential Benefits
- Increased lean muscle mass
- Enhanced muscular hypertrophy
- Potential preservation of muscle during catabolic states
- Improved recovery capacity
- Potential increases in strength and training tolerance
8. Potential Risks / Side Effects
High/Experimental
- Headaches
- Water retention
- Blood pressure changes
- Nosebleeds
- Small blood vessel abnormalities
- Cardiovascular strain
- Unknown long-term organ effects
- Dysregulated tissue growth concerns
9. Half-Life
Estimated half-life discussions for ACE-031 commonly reference approximately 10–15 days.
Because of its long-acting biologic nature, systemic effects and potential adverse reactions may persist for extended periods.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Cardiovascular disease
- Bleeding disorders
- Connective tissue disorders
- Active cancer or cancer history
- Pregnancy or breastfeeding
12. Further Study
ACE-031 Clinical and Mechanistic Research (PubMed Central Search)
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Clinical Trial Archives
- Peer-reviewed muscle physiology journals
14. Last Reviewed
June 2026